Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO at NOSCM 2024 | New Orleans SummerCancer Meeting
Dr. Edgardo Santos' Interview with Mariana Chavez-McGregor, MD, MSc, FASCO

Dr. Chavez-McGregor discusses endocrine and targeted therapies for hormone-positive, HER2-negative breast cancer patients highlighting the importance of individualized therapy due to new drugs and evolving algorithms. She notes the challenge of sequencing treatments, as clinical trials often compare drugs in isolation, while patients receive treatments sequentially. Additionally, she discusses the early use of new molecules in high-risk early-stage breast cancer and the need for further research to address these complexities.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans SummerCancer Meeting
Dr. Edgardo Santos' Interview with Mitesh Borad, MD

Dr. Borad highlighted that RMC-6236’s targeting of KRASin refractory pancreatic cancer achieved 90% disease control and an 8-month median PFS, while cholangiocarcinoma now benefits from IDH and FGFR inhibitors and promising HER2-targeted antibodies (zanidatamab, trastuzumab). In HCC, dualcheckpoint blockade with ipilimumab plus nivolumab has delivered over 30% response rates and 30–40% two- to three-year survival, underscoring the impact of precision and immunotherapy across these malignancies.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans SummerCancer Meeting
Dr. Edgardo Santos' Interview with Richard Kim, MD

Dr. Kim reported that the ESO-EFFECT trial demonstratedsuperior survival and progression-free outcomes with a perioperative chemo-fluid regimen versus neoadjuvant chemo-radiation in resectable esophageal cancer, though definitive data on adjuvant immunotherapy are still lacking. For gastric cancer, he highlighted FDA approval of the HER2-targeted ADC trastuzumab deruxtecan and emerging targets like Claudin 18.2 and FGFR2B, as well as the START study exploring chemo-immunotherapy-anti-TIGIT combinations in patients with CPS >1.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans SummerCancer Meeting
Dr. Edgardo Santos' Interview with Daniel Petrylak, MD

Dr. Petrylak, an international expert on prostate cancer, noted that microsatellite instability occurs in roughly 2% of prostate cancers—making those patients pembrolizumab‐eligible—and championed the use of doublet or triplet regimens in de novo metastatic, hormone‐sensitive disease to markedly improve overall survival. For castration‐resistant disease, he recommended routine DNA repair mutation profiling and PSMA PET imaging—from high-risk localized cases to asymptomatic relapse—and to guide lutetium-177 PSMA therapy.

Interviews withSummit Director Edgardo S. Santos Castillero, MD, FACP, FASCO at NOSCM at 2024 | New Orleans Summer Cancer Meeting

Dr. Edgardo Santos' Interview with Toni Choueiri, MD

Dr. Choueiri highlighted pembrolizumab as the first adjuvant immunotherapy approved for intermediate-high and high-risk kidney cancer—demonstrating overall survival benefits—and confirmed that first-line nivolumab plus ipilimumab improves outcomes, whereas PD-1 rechallenge after progression is unsupported. He also presented HIF-2 inhibitors like belzutifan, which have shown notable progression-free survival gains in phase 3 trials.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting
Dr. Edgardo Santos' Interview with Mark Matrana, MD, MS, FACP

Dr. Matrana highlighted two new gene‐based therapies foradvanced bladder cancer—a non-replicating adenovirus delivering interleukin and a replicating virus combined with pembrolizumab—and noted that the Afrin + pembrolizumab regimen outperformed chemotherapy in metastatic urothelial carcinoma, albeit with toxicities like neuropathy, ocular issues, hyperglycemia, and rash. He also pointed to upcoming strategies pairing immunotherapy with chemotherapy and using circulating tumor DNA to guide monitoring and treatment adjustments.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting

Dr. Edgardo Santos' Interview with Pasquale W. Benedetto, MD

Dr. Benedetto underscored that maintaining dose intensity and following biomarkers are critical to preventing relapses in rare testicular cancer, recommending sperm banking before treatment and annual post-treatment follow-ups. He alsoreassured that most patients can preserve fertility and achieve normal lifespans with experienced, guideline-driven care.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting
NOSCM

Dr. Edgardo Santos' Interview with Sanjiv Agarwala, MD, FASCO

Dr. Sanjeev Agarwalareviewed advances in melanoma therapy, highlighting promising phase II results combining RNA-based vaccines with pembrolizumab, which enhanced anti-tumor response without added toxicity. He noted that dual LAG-3/PD-1 blockade offersefficacy comparable to ipilimumab/nivolumab but with a more favorable safety profile and neoadjuvant ipilimumab for stage III melanoma, which may obviate the need for additional post-surgical treatments.